Skip to main content

Table 3 Patient baseline characteristics by category at baseline

From: Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis

  Categories n (%)  
Characteristic (%) A N = 162 B N = 434 C N = 208 D N = 303 E N = 72 p-value
Study       0.068
 HGLQ 32 (19.8) 123 (28.3) 38 (18.3) 68 (22.4) 0  
 HGKA 82 (50.6) 210 (48.4) 122 (58.7) 142 (46.9) 40 (55.6)  
 HGKB 48 (29.6) 101 (23.3) 48 (23.1) 93 (30.7) 32 (44.4)  
Geographic Region       0.002
 Western Europe 24 (14.8) 79 (18.2) 41 (19.7) 60 (19.8) 10 (13.9)  
 Eastern Europe 53 (32.7) 115 (26.5) 55 (26.4) 72 (23.8) 18 (25.0)  
 Americas 60 (37.0) 210 (48.4) 79 (38.0) 160 (52.8) 41 (56.9)  
 Other 25 (15.4) 30 (6.9) 33 (15.9) 11 (3.6) 3 (4.2)  
Gender       0.491
 Female 59 (36.4) 145 (33.4) 69 (33.2) 93 (30.7) 25 (34.7)  
 Male 103 (63.6) 289 (66.6) 139 (66.8) 210 (69.3) 47 (65.3)  
EPS       0.013
 Yes 12 (7.4) 58 (13.4) 30 (14.4) 48 (15.8) 16 (22.2)  
Working Status1       <0.001
 Paid work 72 (44.4) 50 (11.5) 70 (33.7) 28 (9.2) 3 (4.2)  
 Retired 19 (11.7) 61 (14.1) 15 (7.2) 23 (7.6) 4 (5.6)  
 Unemployed dis. 24 (14.8) 194 (44.7) 54 (26.0) 177 (58.4) 46 (63.9)  
Cross-sectional remiss.       <0.001
 No 25 (15.4) 168 (38.7) 89 (42.8) 216 (71.3) 71 (98.6)  
 Yes 137 (84.6) 266 (61.3) 119 (57.2) 87 (28.7) 1 (1.4)  
Mean (SD)       
Age [year] 37.6 (10.6) 40.7 (11.6) 37.9 (11.1) 40.0 (11.2) 40.1 (11.3) 0.002
CGI-S 2.34 (0.85) 2.96 (0.89) 3.06 (0.84) 3.56 (0.76) 4.01 (0.84) <0.001
No. of previous episodes 1.07 (1.25) 1.60 (2.50) 1.34 (1.31) 1.54 (1.68) 1.85 (1.75) 0.017
  1. 1 Only the 3 largest categories (>10% of all patients) are shown as working status; 6 additional categories were defined and were included in the statistical analysis (self employed, student, volunteer, keeping house, unemployed unrelated),CGI-S: Clinical Global Impression – Severity, EPS: Extrapyramidal Symptoms, SD: standard deviation.